FindTrial
Sign In

Chimeric Antigen Receptor–Modified T Cells combined with donor lymphocyte infusion or tyrosine kinase inhibitors to treat the acute lymphoblastic leukemia patients who experienced relapse after allogeneic hematopoietic stem cell transplantation

Chimeric Antigen Receptor–Modified T Cells combined with donor lymphocyte infusion or tyrosine kinase inhibitors to treat the acute lymphoblastic leukemia patients who experienced relapse after allogeneic hematopoietic stem cell transplantation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017425
Enrollment
Unknown
Registered
2018-07-30
Start date
2018-08-01
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute leukemia

Interventions

Group 1:Donor lymphocyte infusion
Group 2:tyrosine kinase inhibitors

Sponsors

Peking University People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Acute B-cell lymphoblastic leukemia; 2. Relapse after allogeneic hematopoietic stem cell transplantation; 3. Receiving Chimeric Antigen Receptor–Modified T Cells treatment and achieve complete remission.

Exclusion criteria

Exclusion criteria: 1. Non-complete remission after Chimeric Antigen Receptor–Modified T Cells treatment; 2. Active graft-versus-host disease; 3. Active infection; 4. Severe myelosuppression; 5. Organ failure.

Design outcomes

Primary

MeasureTime frame
Relapse;—

Secondary

MeasureTime frame
Leukemia-free survival;Overall survival;Treatment-related mortality;—

Countries

China

Contacts

Public ContactChen Yuhong

Peking University People's Hospital

chch9929@vip.sina.com+86 15010293966

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026